Immunocore Holdings plc (NASDAQ:IMCR) Shares Purchased by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company boosted its holdings in Immunocore Holdings plc (NASDAQ:IMCR - Free Report) by 37.2% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 121,753 shares of the company's stock after purchasing an additional 33,003 shares during the quarter. The Manufacturers Life Insurance Company owned about 0.24% of Immunocore worth $4,126,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Wellington Management Group LLP raised its position in Immunocore by 10.2% in the 4th quarter. Wellington Management Group LLP now owns 4,312,611 shares of the company's stock valued at $294,638,000 after purchasing an additional 399,201 shares during the last quarter. Primecap Management Co. CA raised its position in Immunocore by 3,841.6% in the 2nd quarter. Primecap Management Co. CA now owns 1,951,070 shares of the company's stock valued at $66,122,000 after purchasing an additional 1,901,570 shares during the last quarter. Bellevue Group AG raised its position in Immunocore by 4,817.1% in the 4th quarter. Bellevue Group AG now owns 976,054 shares of the company's stock valued at $66,684,000 after purchasing an additional 956,204 shares during the last quarter. Armistice Capital LLC raised its position in Immunocore by 495.1% in the 2nd quarter. Armistice Capital LLC now owns 976,000 shares of the company's stock valued at $33,077,000 after purchasing an additional 812,000 shares during the last quarter. Finally, Fiera Capital Corp raised its position in Immunocore by 1.1% in the 2nd quarter. Fiera Capital Corp now owns 875,593 shares of the company's stock valued at $29,674,000 after purchasing an additional 9,181 shares during the last quarter. Hedge funds and other institutional investors own 84.50% of the company's stock.

Wall Street Analyst Weigh In

Several research firms recently commented on IMCR. Guggenheim downgraded shares of Immunocore from a "buy" rating to a "neutral" rating in a research report on Monday. HC Wainwright reissued a "buy" rating and issued a $100.00 price objective on shares of Immunocore in a research note on Tuesday, September 17th. Needham & Company LLC lowered their price target on shares of Immunocore from $81.00 to $78.00 and set a "buy" rating on the stock in a research note on Tuesday, September 17th. Barclays lowered their price target on shares of Immunocore from $92.00 to $66.00 and set an "overweight" rating on the stock in a research note on Friday, August 9th. Finally, Oppenheimer reissued an "outperform" rating and issued a $89.00 price objective (up from $87.00) on shares of Immunocore in a research note on Friday, August 9th. Two analysts have rated the stock with a hold rating and ten have given a buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $80.40.

Immunocore Trading Down 0.6 %

Shares of IMCR stock traded down $0.18 during trading hours on Tuesday, hitting $30.57. 363,023 shares of the company were exchanged, compared to its average volume of 559,222. The firm has a market cap of $1.53 billion, a PE ratio of -25.06 and a beta of 0.72. Immunocore Holdings plc has a 1 year low of $29.72 and a 1 year high of $76.98. The company has a quick ratio of 5.15, a current ratio of 5.17 and a debt-to-equity ratio of 1.31. The firm has a fifty day moving average of $34.89 and a 200 day moving average of $43.88.

Immunocore (NASDAQ:IMCR - Get Free Report) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($0.48) by $0.25. The business had revenue of $75.40 million for the quarter, compared to analyst estimates of $74.58 million. Immunocore had a negative net margin of 19.16% and a negative return on equity of 14.68%. The company's revenue was up 26.2% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.37) EPS. Analysts expect that Immunocore Holdings plc will post -1.79 earnings per share for the current year.

Immunocore Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.